Evotec SE Stock Deutsche Boerse AG
Stocks
EVTA
US30050E1055
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Deutsche Boerse AG
02:08:54 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 1.260 EUR | -5.26% |
|
-5.97% | -52.27% |
| 09-18 | Evotec at the top of the SDax - Positive comments at a conference | DP |
| 09-09 | Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment | MT |
| Market Cap | 497M 570M 468M 426M 799M 54.57B 800M 5.6B 2.16B 27.8B 2.14B 2.09B 89.7B | P/E 2026 * |
-2.38x | P/E 2027 * | -6.49x |
|---|---|---|---|---|---|
| Enterprise Value | 639M 733M 602M 548M 1.03B 70.26B 1.03B 7.21B 2.78B 35.79B 2.76B 2.69B 116B | EV / Sales 2026 * |
1.06x | EV / Sales 2027 * | 0.91x |
| Free-Float |
89.91% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EVO | Delayed | |
CBOE
| EVO | Real-time | |
|
Boerse Muenchen
| EVTA | Real-time | |
|
Deutsche Boerse AG
| EVTA | Delayed | |
|
Börse Stuttgart
| EVTA | Delayed |
Last Transcript: Evotec SE
| 1 day | -5.26% | ||
| 1 week | -5.97% | ||
| Current month | -17.65% | ||
| 1 month | -17.65% | ||
| 3 months | -41.67% | ||
| 6 months | -35.05% | ||
| Current year | -52.27% |
| 1 week | 1.16 |  | 1.68 |
| 1 month | 1.16 | | 1.77 |
| Current year | 1.16 | | 3.2 |
| 1 year | 1.16 | | 3.54 |
| 3 years | 1.16 | | 11 |
| 5 years | 1.16 | | 85.5 |
| 10 years | 1.16 | | 85.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 2024-06-30 | |
| Director of Finance/CFO | - | 2026-04-30 | |
Ingrid Müller
COO | Chief Operating Officer | - | 2026-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Roland Sackers
BRD | Director/Board Member | 58 | 2019-06-18 |
| Director/Board Member | 64 | 2021-05-31 | |
Duncan McHale
BRD | Director/Board Member | 59 | 2024-06-09 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.26% | -5.97% | - | - | 570M | |
| +2.17% | +4.36% | +3.66% | +31.50% | 46.68B | |
| +0.00% | -0.24% | +43.23% | +35.36% | 44.42B | |
| +0.70% | -5.71% | +334.95% | +543.87% | 41.32B | |
| -1.02% | +4.37% | +7.05% | +89.75% | 41.58B | |
| +1.11% | +1.45% | +11.52% | +45.96% | 30.14B | |
| -0.47% | +0.08% | +24.67% | +155.87% | 17.42B | |
| +1.08% | -0.31% | - | - | 15.6B | |
| +0.56% | +6.72% | +25.11% | +42.95% | 15.54B | |
| -0.25% | +13.23% | -9.21% | - | 14.08B | |
| Average | -0.15% | +3.55% | +55.12% | +135.04% | 29.64B | |
| Weighted average by Cap. | +0.49% | +2.11% | +68.72% | +143.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 601M 689M 566M 515M 966M 66.02B 968M 6.78B 2.61B 33.63B 2.59B 2.53B 109B | 724M 830M 682M 621M 1.16B 79.56B 1.17B 8.17B 3.15B 40.53B 3.12B 3.05B 131B |
| Net income | -202M -232M -190M -173M -325M -22.19B -325M -2.28B -878M -11.31B -870M -851M -36.48B | -48.25M -55.34M -45.44M -41.39M -77.59M -5.3B -77.69M -544M -210M -2.7B -208M -203M -8.71B |
| Net Debt | 143M 164M 135M 123M 230M 15.7B 230M 1.61B 621M 8B 615M 602M 25.8B | 162M 186M 153M 139M 261M 17.82B 261M 1.83B 705M 9.08B 699M 683M 29.29B |
| Date | Price | Change |
|---|---|---|
| 26-09-22 | €1.260 | -5.26% |
| 26-09-21 | €1.330 | -3.62% |
| 26-09-18 | €1.380 | +18.97% |
| 26-09-17 | €1.160 | -7.20% |
| 26-09-16 | €1.250 | -6.72% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EVT Stock
- EVTA Stock
Select your edition
All financial news and data tailored to specific country editions
